Cited by 116Heat shock proteins researchProtein Degradation and InhibitorsUbiquitin and proteasome pathways

Mechanistic studies of Sansalvamide A-amide: An allosteric modulator of Hsp90

Open access
Vasko, Robert C., Rodriguez, Rodrigo A., Cunningham, Christian N., Ardi, Veronica C., Agard, David A., McAlpine, Shelli R.·2010·ACS Medicinal Chemistry Letters

Abstract

Herein we show that San A-amide, a structurally unique molecule, influences a subset of cancer-related pathways involving Hsp90. We show that San A-amide specifically binds to the N-middle domain of Hsp90 allosterically disrupts the binding of proteins thought to interact with the Hsp90 C-terminal domain, while having no effect on an N-terminal domain client protein. This unique mechanism suggests that San A-amide is a potential tool for studying C-terminal binding proteins of Hsp90 as well as a promising lead in the development of new cancer therapeutics.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/ml900003t

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sansalvamide A binds to the N-middle domain of HSP90 and allosterically inhibits protein complex formation necessary for promotion of tumor growth.

    “Sansalvamide A binds to the N-middle domain of HSP90 and allosterically inhibits protein complex formation, which is necessary for promotion of tumor growth [187].”

    From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [187]

    The paper reports that Sansalvamide A-amide binds preferentially to Hsp90’s N-middle domain and allosterically disrupts its interactions with the proteins IP6K2 and FKBP52 (Abstract). It distinguishes this derivative from Sansalvamide A itself, so it does not establish the stated mechanism for the unmodified compound. It links Hsp90 to cancer cell growth but does not establish that the particular disrupted complexes are necessary for tumor growth. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vasko, R. C., Rodriguez, R. A., Cunningham, C. N., Ardi, V. C., Agard, D. A., & McAlpine, S. R.
Affiliations
Howard Hughes Medical Institute (US)
Corresponding author
McAlpine, Shelli R.
Venue
ACS Medicinal Chemistry Letters
Published
2010-01-04
Volume
1
Issue
1
Pages
4-8
ISSN
1948-5875 (ISSN-L)
OpenAlex
W2007103196
Cited by
105
References
39
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 6 · 2017: 3 · 2016: 8 · 2015: 11 · 2014: 12 · 2013: 8 · 2012: 8
FWCI
3.26
Type
journal article
Language
en
Open access
Locations
  • ACS Medicinal Chemistry Letters (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
Funders
  • National Cancer Institute (R01CA137873)
  • National Institute of General Medical Sciences (T34GM008303)
  • Fogarty International Center (T37TW000067)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
HSP90, allosteric modulators, C-terminal domain, protein binding, cancer therapeutics, lead compounds, mechanism of action

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review